BBOT - NASDAQ

BridgeBio Oncology Therapeutics Inc.

BBOT·NASDAQ

$8.23

-0.48%

HealthcareBiotechnology

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$659.28M

EPS-4.3000

P/E Ratio-1.91

Earnings Date06/04/2026

bbot

Long Term Debt

Last Annual Value

2.24M

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

BridgeBio Oncology Therapeutics Inc. Competitors Analysis of Long Term Debt

BBOT · NASDAQ

Company	Long Term Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT	2.24M	N/A	N/A	N/A
UroGen Pharma Ltd. NASDAQ:URGN	122.21M	7.4%	N/A	N/A
AnaptysBio, Inc. NASDAQ:ANAB	12.03M	N/A	N/A	-1.4%
Tango Therapeutics, Inc. NASDAQ:TNGX	30.83M	N/A	N/A	N/A
Kodiak Sciences Inc. NASDAQ:KOD	47.12M	-22.2%	-14.0%	N/A
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT	2.06M	-75.3%	-53.0%	N/A
Xencor, Inc. NASDAQ:XNCR	76.48M	73.5%	N/A	N/A
Nurix Therapeutics, Inc. NASDAQ:NRIX	0.00	N/A	N/A	N/A
Septerna, Inc. NASDAQ:SEPN	21.41M	N/A	N/A	N/A

BridgeBio Oncology Therapeutics Inc. Fair Value Envelope

BBOT · NASDAQ

Our analysis suggests that BBOT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.23, this represents a potential HIDDEN relative to our calculated worth for BridgeBio Oncology Therapeutics Inc..

HIDDEN

Intrinsic Value

Current Price: $8.23

Related Guides

Blog Categories

Continue your BBOT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.